3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
265
Magnetic Resonance Spectroscopy
216
pembrolizumab
212
Carboplatin
173
Biopsy
162
Cisplatin
155
Nivolumab
147
Cyclophosphamide
131
Paclitaxel
116
Radiotherapy
115
Gemcitabine
110
Bevacizumab
91
durvalumab
84
Dexamethasone
79
Rituximab
74
Oxaliplatin
71
atezolizumab
67
Fluorouracil
66
Doxorubicin
65
Capecitabine
65
Docetaxel
64
venetoclax
63
Etoposide
63
Radiosurgery
58
Radiation
57
Prednisone
55
Ipilimumab
55
Cytarabine
55
Pemetrexed
54
Lenalidomide
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
trastuzumab duocarmazine
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled